4/20
08:02 am
ngne
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors [Yahoo! Finance]
Low
Report
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors [Yahoo! Finance]
4/20
07:30 am
ngne
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Low
Report
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
4/8
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/6
11:25 am
ngne
Neurogene (NGNE) had its price target lowered by Canaccord Genuity Group Inc. from $200.00 to $180.00. They now have a "buy" rating on the stock.
Low
Report
Neurogene (NGNE) had its price target lowered by Canaccord Genuity Group Inc. from $200.00 to $180.00. They now have a "buy" rating on the stock.
3/24
07:39 am
ngne
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]
Medium
Report
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]
3/24
07:30 am
ngne
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Medium
Report
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
3/11
07:30 am
ngne
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Low
Report
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
3/3
04:11 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/3
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
01:33 pm
ngne
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
Medium
Report
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
2/26
04:14 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
2/26
04:01 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
2/5
07:30 am
ngne
Neurogene to Participate in Upcoming Investor Conferences
Medium
Report
Neurogene to Participate in Upcoming Investor Conferences
2/4
04:01 pm
ngne
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/26
09:26 am
ngne
Neurogene (NASDAQ:NGNE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $50.00 price target on the stock.
Medium
Report
Neurogene (NASDAQ:NGNE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $50.00 price target on the stock.